View Future GrowthCann Group 過去の業績過去 基準チェック /36Cann Groupは、平均年間1.2%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間8.5% 11.8%収益成長率で 成長しています。 Cann Groupの自己資本利益率は43%であり、純利益率は130.3%です。主要情報1.18%収益成長率14.25%EPS成長率Pharmaceuticals 業界の成長7.33%収益成長率11.76%株主資本利益率42.97%ネット・マージン130.29%前回の決算情報31 Dec 2025最近の業績更新Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.042 loss per share (vs AU$0.12 loss in FY 2024)Full year 2025 results: AU$0.042 loss per share (improved from AU$0.12 loss in FY 2024). Revenue: AU$13.3m (down 28% from FY 2024). Net loss: AU$22.3m (loss narrowed 56% from FY 2024).Reported Earnings • Sep 01Full year 2024 earnings released: AU$0.12 loss per share (vs AU$0.091 loss in FY 2023)Full year 2024 results: AU$0.12 loss per share (further deteriorated from AU$0.091 loss in FY 2023). Revenue: AU$19.1m (down 7.6% from FY 2023). Net loss: AU$51.2m (loss widened 52% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings.お知らせ • Jul 24Cann Group Limited to Report Fiscal Year 2024 Results on Aug 30, 2024Cann Group Limited announced that they will report fiscal year 2024 results on Aug 30, 2024Reported Earnings • Aug 28Full year 2023 earnings released: AU$0.091 loss per share (vs AU$0.079 loss in FY 2022)Full year 2023 results: AU$0.091 loss per share (further deteriorated from AU$0.079 loss in FY 2022). Revenue: AU$21.7m (up 93% from FY 2022). Net loss: AU$33.8m (loss widened 28% from FY 2022). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 26First half 2023 earnings released: AU$0.053 loss per share (vs AU$0.028 loss in 1H 2022)First half 2023 results: AU$0.053 loss per share (further deteriorated from AU$0.028 loss in 1H 2022). Net loss: AU$18.8m (loss widened 128% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 30Full year 2022 earnings released: AU$0.079 loss per share (vs AU$0.098 loss in FY 2021)Full year 2022 results: AU$0.079 loss per share. Revenue: AU$11.2m (up 32% from FY 2021). Net loss: AU$26.5m (loss widened 5.4% from FY 2021).すべての更新を表示Recent updatesお知らせ • Dec 05Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 6.5 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 6.5 million. Security Name: Ordinay Shares Security Type: Common Stock Securities Offered: 120,395,238 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069 Security Name: Ordinay Shares Security Type: Common Stock Securities Offered: 444,822,153 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069 Transaction Features: Subsequent Direct Listingお知らせ • Oct 29Cann Group Limited, Annual General Meeting, Nov 28, 2025Cann Group Limited, Annual General Meeting, Nov 28, 2025. Location: hwl ebsworth lawyers, level 8, 447 collins street, melbourne, vic 3000, melbourne Australiaお知らせ • Oct 27+ 1 more updateCann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 217,391,304 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.042 loss per share (vs AU$0.12 loss in FY 2024)Full year 2025 results: AU$0.042 loss per share (improved from AU$0.12 loss in FY 2024). Revenue: AU$13.3m (down 28% from FY 2024). Net loss: AU$22.3m (loss narrowed 56% from FY 2024).Board Change • Aug 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Peter Kopanidis was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jul 02+ 1 more updateCann Group Limited Announces Appointment of Jenni Pilcher as Permanent Managing Director Contract RenewedCann Group Limited announced that it has executed a permanent employment agreement with Ms Jenni Pilcher, in the role of Managing Director (New Employment Contract). This follows the Company's previous announcement, made on the 15 July 2024, relating to the appointment of Ms. Jenni Pilcher as Managing Director, on a fixed-term contract which ended 1 July 2025 (Previous Employment Contract). With the exception of the contract term (now a permanent position requiring four (4) months' notice for termination), the remaining key terms of the New Employment Contract are consistent with the key terms of the Previous Employment Contract, as described in the 15 July 2024 announcement.お知らせ • Apr 14Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 0.711902 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 0.711902 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 41,876,573 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Apr 08Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.711902 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.711902 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 41,876,573 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Mar 12Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.105 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.105 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,000,000 Price\Range: AUD 0.015 Transaction Features: Subsequent Direct Listingお知らせ • Dec 06Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 2.255994 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 2.255994 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 50,724,489 Price\Range: AUD 0.04 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,675,343 Price\Range: AUD 0.04 Security Features: Attached Options Transaction Features: Rights Offeringお知らせ • Oct 09Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.252486 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.252486 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 156,312,161 Price\Range: AUD 0.04 Security Features: Attached Options Transaction Features: Rights Offeringお知らせ • Sep 03Cann Group Limited, Annual General Meeting, Oct 28, 2024Cann Group Limited, Annual General Meeting, Oct 28, 2024.Reported Earnings • Sep 01Full year 2024 earnings released: AU$0.12 loss per share (vs AU$0.091 loss in FY 2023)Full year 2024 results: AU$0.12 loss per share (further deteriorated from AU$0.091 loss in FY 2023). Revenue: AU$19.1m (down 7.6% from FY 2023). Net loss: AU$51.2m (loss widened 52% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings.お知らせ • Jul 24Cann Group Limited to Report Fiscal Year 2024 Results on Aug 30, 2024Cann Group Limited announced that they will report fiscal year 2024 results on Aug 30, 2024お知らせ • Jul 15+ 1 more updateCann Group Limited Appoints Jenni Pilcher as Managing DirectorCann Group Limited announced that it has executed an employment agreement to formally appoint Ms. Jenni Pilcher to the role of CEO & Managing Director. Jenni joined Cann as a Non-executive Director on 15 September 2020. In February 2024, Jenni stepped into an Executive Director role to provide financial oversight of the Company, transitioning to Interim CEO following the notice of resignation of the CEO on 21 March 2024. Chairman, Julian Chick, commented: "Since stepping in as Executive Director in February, Jenni has implemented a restructure and cost savings plan which will generate at least $2.15 million savings per annum. Following on from this, Jenni successfully managed the re-release of the Company's half-year financial report in May accompanied by an audit review report free from disclaimers, secured a further $5 million debt to fund the business, and achieved the ASX's reinstatement of CAN securities to trading in June. Jenni has over 15 years of senior finance executive experience in the medical, biotechnology and technology sectors, within small-mid cap ASX-listed companies. In addition to financial management, investor relations and corporate governance experience, Jenni has successfully completed multiple capital raisings and M&A transactions, including company acquisitions, asset sales, and a takeover defense. Most recently, Jenni was Chief Financial Officer & Company Secretary of technology communications company Whispir Ltd, and prior to that was CFO & Company Secretary of digital imaging company, Mach7 Technologies. She has also previously held CFO roles with Australia biotechnology companies Alchemia Limited and Mesoblast Limited. Jenni is a member of Chartered Accountants Australia & New Zealand, a Graduate of the Governance Institute of Australia, and has a Bachelor of Business Studies (majoring in accounting) from Massey University in New Zealand. Ms. Pilcher will be appointed for a fixed term ending on 1 July 2025, subject to termination by either party. The fixed term can be extended at any time by mutual agreement, in writing, between Ms. Pilcher and the Company.Board Change • Jun 05Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Doug Rathbone was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Mar 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$20m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$20m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 24% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (€16.3m market cap, or US$17.7m).お知らせ • Jan 08+ 1 more updateCann Group Limited Appoints Tony Di Pietro as Joint Company Secretary of Head of Legal and Regulatory AffairsCann Group Limited announced that Tony Di Pietro will act as joint Company Secretary with Steven Notaro, Head of Legal and Regulatory Affairs at Cann Group. . Having spent the past two decades at ASX-listed companies, Mr. Di Pietro boasts extensive experience as CFO/Company Secretary in the med-tech industry, with his last three roles at Sienna Cancer Diagnostics Limited (November 2014 - July 2020), INOVIQ Limited (July 2020 - November 2022) and Genetic Technologies Limited (November 2022 - present). In his most recent role at Genetic Technologies, Mr. Di Pietro managed a capital raising of $5 million from US-based investors and was responsible for both US and Australian due diligence activities and compliance with both ASX/Corporations Act & NASDAQ/SEC regulations. Mr. Di Pietro's qualifications include: A Bachelor of Commerce (BCom),Accounting and Finance, from Swinburne University of Technology;Chartered Accountants (CA) accreditation (1989-2000); Graduate Diploma of Applied Corporate Governancefrom the Governance Institute of Australia(2012-2014); and Completed the Company Directors Course at the Australian Institute of Company Directors in 2018.お知らせ • Dec 04+ 1 more updateCann Group Limited Announces Resignation of Deborah Ambrosini as Chief Financial Officer, Effective December 22, 2023Cann Group Limited announced that its Chief Financial Officer Deborah Ambrosini, has resigned for personal reasons effective December 22, 2023.お知らせ • Nov 22+ 1 more updateCann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.3756 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.3756 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,333,333 Price\Range: AUD 0.11268 Transaction Features: Subsequent Direct Listingお知らせ • Aug 29Cann Group Limited, Annual General Meeting, Oct 26, 2023Cann Group Limited, Annual General Meeting, Oct 26, 2023, at 10:00 AUS Eastern Standard Time.Reported Earnings • Aug 28Full year 2023 earnings released: AU$0.091 loss per share (vs AU$0.079 loss in FY 2022)Full year 2023 results: AU$0.091 loss per share (further deteriorated from AU$0.079 loss in FY 2022). Revenue: AU$21.7m (up 93% from FY 2022). Net loss: AU$33.8m (loss widened 28% from FY 2022). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.New Risk • Aug 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$35m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 35% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (€31.6m market cap, or US$34.2m).お知らせ • Jul 26Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 11.658446 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 11.658446 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 97,153,716 Price\Range: AUD 0.12 Discount Per Security: AUD 0.0024 Security Features: Attached Options Transaction Features: Rights Offeringお知らせ • Jul 06Cann Group Limited Provides Revenue Guidance for the Year Ended June 30, 2023Cann Group Limited provided revenue guidance for the year ended June 30, 2023. Cann expects to report unaudited product sales revenue of approximately $13.5 million, before accounting for services, for the 12 months ending 30 June 2023 representing a 111% increase on FY22 revenue ($6.4 million). Strong market demand saw revenue from the sale of dried flower products increase by approximately 500% on FY22 and is the base for continued growth as the company scales up production. This improvement was driven by the domestic market, with the strong sales momentum supported by new clients entering into supply agreements, and several existing clients with repeat orders. Customer acquisition has been strengthened by Cann's ability to supply consistent quality, GMP product from the flagship facility in Mildura, achieved through state- of-the-art cultivation and manufacturing processes. FY23 production output at Mildura was 2.2 tonnes. In May 2023, Cann planted the largest crop in the Company's history, representing 8 tons annualised yield. This crop will be harvested in July 2023.Reported Earnings • Feb 26First half 2023 earnings released: AU$0.053 loss per share (vs AU$0.028 loss in 1H 2022)First half 2023 results: AU$0.053 loss per share (further deteriorated from AU$0.028 loss in 1H 2022). Net loss: AU$18.8m (loss widened 128% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.お知らせ • Jan 20Cann Group Limited Announces Preliminary Results from Their Phase 3 Clinical TrailCann Group Limited announced preliminary results from their Phase 3 clinical trail. Trial compared the efficacy of low dose Satipharm® CBD capsules to placebo in treating sleep disturbances. Three doses of Satipharm® CBD capsules were compared to placebo in a randomised, double-blind, placebo-controlled, multicentre clinical trial that included a total of 257 participants with sleep disturbances. Preliminary view of the analysis of the primary end-points have not shown a statistically superior response compared to placebo. Cann Group expects these trial results will delay submission of the registration application to the Therapeutic Goods Administration (TGA) for this indication. Once the full data set (including the secondary end-points) and report of the clinical trial is delivered to the company, Cann Group will evaluate the data and review its approach for this indication. A market update will be published once that review is complete.お知らせ • Jan 10Cann Group Limited Announces Chief Executive Officer ChangesCann Group Limited announced that Peter Koetsier has been appointed to the role of Chief Executive Officer (CEO) and will commence in the role on January 16, 2023. Mr. Koetsier will replace Peter Crock, who was appointed on April 19, 2016 and announced on October 24, 2022 that he would be stepping down as CEO of the Company. Mr. Koetsier brings to Cann more than 30 years of general management, marketing and commercial leadership roles within global pharmaceutical companies. He has most recently been Head of Asia Pacific for French biopharmaceutical company, Ipsen, where he developed and led the implementation of a successful growth strategy which included the commercial launch of new brands. Previous roles include General Manager of Australia/New Zealand (Ipsen) and senior management positions with Astra/Zeneca, UK, and Bristol-Myers Squibb in Europe. Mr. Koetsier has a bachelor's degree in science (pharmacology, immunology) and a diploma in education (science, biology) from Monash University and is a graduate of the INSEAD CEDEP General Management Program.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Doug Rathbone was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 30Full year 2022 earnings released: AU$0.079 loss per share (vs AU$0.098 loss in FY 2021)Full year 2022 results: AU$0.079 loss per share. Revenue: AU$11.2m (up 32% from FY 2021). Net loss: AU$26.5m (loss widened 5.4% from FY 2021).Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Doug Rathbone was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 21First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: AU$0.028 loss per share (up from AU$0.05 loss in 1H 2021). Net loss: AU$8.28m (loss narrowed 12% from 1H 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 277%, compared to a 7.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings.Executive Departure • Sep 07Chief Financial Officer Greg Bullock has left the companyDuring their tenure, earnings grew by 46% annually compared to the industry average of 8.2%. On the 1st of September, Greg Bullock left the company after 1.3 in the role. We don't have any record of a personal shareholding under Greg's name. Greg is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.42 years, which is considered inexperienced in the Simply Wall St Risk Model.Reported Earnings • Aug 24Full year 2021 earnings released: AU$0.097 loss per share (vs AU$0.12 loss in FY 2020)Full year 2021 results: Net loss: AU$25.1m (loss widened 48% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings.Reported Earnings • Feb 24First half 2021 earnings released: AU$0.05 loss per share (vs AU$0.06 loss in 1H 2020)First half 2021 results: Net loss: AU$9.40m (loss widened 12% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 41% per year whereas the company’s share price has fallen by 39% per year.Is New 90 Day High Low • Feb 10New 90-day high: €0.52The company is up 167% from its price of €0.19 on 11 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period.Is New 90 Day High Low • Nov 24New 90-day high: €0.30The company is up 21% from its price of €0.25 on 26 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 3.0% over the same period.Is New 90 Day High Low • Oct 12New 90-day low: €0.23The company is down 54% from its price of €0.50 on 14 July 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 7.0% over the same period.収支内訳Cann Group の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:CVJ 収益、費用、利益 ( )AUD Millions日付収益収益G+A経費研究開発費31 Dec 25111512130 Sep 2512-413130 Jun 2513-2213131 Mar 2514-3514131 Dec 2416-4814030 Sep 2417-4916130 Jun 2418-5119131 Mar 2420-4020131 Dec 2321-2920230 Sep 2321-3220330 Jun 2321-3419431 Mar 2318-3523431 Dec 2214-3727530 Sep 2213-3227430 Jun 2211-2628331 Mar 2210-2527231 Dec 219-2426230 Sep 219-2525230 Jun 219-2523231 Mar 217-2219231 Dec 206-1815230 Sep 204-1714230 Jun 202-1714131 Mar 202-1615131 Dec 193-1416130 Sep 193-1315130 Jun 193-1113131 Mar 192-1011131 Dec 181-89130 Sep 181-67130 Jun 181-56131 Mar 180-44131 Dec 170-32030 Sep 170-32130 Jun 170-32130 Jun 160-110質の高い収益: CVJ 非現金収入 のレベルが高いです。利益率の向上: CVJ過去に利益を上げました。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: CVJ過去 5 年間で収益を上げており、収益は年間1.2%増加しています。成長の加速: CVJは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。収益対業界: CVJ昨年収益を上げたため、昨年の収益成長をPharmaceuticals業界 ( 15.6% ) と比較することは困難です。株主資本利益率高いROE: CVJの 自己資本利益率 ( 43% ) は 傑出している と考えられます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/12 01:05終値2026/07/10 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cann Group Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Cameron BellCanaccord GenuityPaul JenszPAC Partners Securities Pty. Ltd.
Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.042 loss per share (vs AU$0.12 loss in FY 2024)Full year 2025 results: AU$0.042 loss per share (improved from AU$0.12 loss in FY 2024). Revenue: AU$13.3m (down 28% from FY 2024). Net loss: AU$22.3m (loss narrowed 56% from FY 2024).
Reported Earnings • Sep 01Full year 2024 earnings released: AU$0.12 loss per share (vs AU$0.091 loss in FY 2023)Full year 2024 results: AU$0.12 loss per share (further deteriorated from AU$0.091 loss in FY 2023). Revenue: AU$19.1m (down 7.6% from FY 2023). Net loss: AU$51.2m (loss widened 52% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings.
お知らせ • Jul 24Cann Group Limited to Report Fiscal Year 2024 Results on Aug 30, 2024Cann Group Limited announced that they will report fiscal year 2024 results on Aug 30, 2024
Reported Earnings • Aug 28Full year 2023 earnings released: AU$0.091 loss per share (vs AU$0.079 loss in FY 2022)Full year 2023 results: AU$0.091 loss per share (further deteriorated from AU$0.079 loss in FY 2022). Revenue: AU$21.7m (up 93% from FY 2022). Net loss: AU$33.8m (loss widened 28% from FY 2022). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 26First half 2023 earnings released: AU$0.053 loss per share (vs AU$0.028 loss in 1H 2022)First half 2023 results: AU$0.053 loss per share (further deteriorated from AU$0.028 loss in 1H 2022). Net loss: AU$18.8m (loss widened 128% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 30Full year 2022 earnings released: AU$0.079 loss per share (vs AU$0.098 loss in FY 2021)Full year 2022 results: AU$0.079 loss per share. Revenue: AU$11.2m (up 32% from FY 2021). Net loss: AU$26.5m (loss widened 5.4% from FY 2021).
お知らせ • Dec 05Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 6.5 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 6.5 million. Security Name: Ordinay Shares Security Type: Common Stock Securities Offered: 120,395,238 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069 Security Name: Ordinay Shares Security Type: Common Stock Securities Offered: 444,822,153 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 29Cann Group Limited, Annual General Meeting, Nov 28, 2025Cann Group Limited, Annual General Meeting, Nov 28, 2025. Location: hwl ebsworth lawyers, level 8, 447 collins street, melbourne, vic 3000, melbourne Australia
お知らせ • Oct 27+ 1 more updateCann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 217,391,304 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069
Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.042 loss per share (vs AU$0.12 loss in FY 2024)Full year 2025 results: AU$0.042 loss per share (improved from AU$0.12 loss in FY 2024). Revenue: AU$13.3m (down 28% from FY 2024). Net loss: AU$22.3m (loss narrowed 56% from FY 2024).
Board Change • Aug 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Peter Kopanidis was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 02+ 1 more updateCann Group Limited Announces Appointment of Jenni Pilcher as Permanent Managing Director Contract RenewedCann Group Limited announced that it has executed a permanent employment agreement with Ms Jenni Pilcher, in the role of Managing Director (New Employment Contract). This follows the Company's previous announcement, made on the 15 July 2024, relating to the appointment of Ms. Jenni Pilcher as Managing Director, on a fixed-term contract which ended 1 July 2025 (Previous Employment Contract). With the exception of the contract term (now a permanent position requiring four (4) months' notice for termination), the remaining key terms of the New Employment Contract are consistent with the key terms of the Previous Employment Contract, as described in the 15 July 2024 announcement.
お知らせ • Apr 14Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 0.711902 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 0.711902 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 41,876,573 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Apr 08Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.711902 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.711902 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 41,876,573 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Mar 12Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.105 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.105 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,000,000 Price\Range: AUD 0.015 Transaction Features: Subsequent Direct Listing
お知らせ • Dec 06Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 2.255994 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 2.255994 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 50,724,489 Price\Range: AUD 0.04 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,675,343 Price\Range: AUD 0.04 Security Features: Attached Options Transaction Features: Rights Offering
お知らせ • Oct 09Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.252486 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.252486 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 156,312,161 Price\Range: AUD 0.04 Security Features: Attached Options Transaction Features: Rights Offering
お知らせ • Sep 03Cann Group Limited, Annual General Meeting, Oct 28, 2024Cann Group Limited, Annual General Meeting, Oct 28, 2024.
Reported Earnings • Sep 01Full year 2024 earnings released: AU$0.12 loss per share (vs AU$0.091 loss in FY 2023)Full year 2024 results: AU$0.12 loss per share (further deteriorated from AU$0.091 loss in FY 2023). Revenue: AU$19.1m (down 7.6% from FY 2023). Net loss: AU$51.2m (loss widened 52% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings.
お知らせ • Jul 24Cann Group Limited to Report Fiscal Year 2024 Results on Aug 30, 2024Cann Group Limited announced that they will report fiscal year 2024 results on Aug 30, 2024
お知らせ • Jul 15+ 1 more updateCann Group Limited Appoints Jenni Pilcher as Managing DirectorCann Group Limited announced that it has executed an employment agreement to formally appoint Ms. Jenni Pilcher to the role of CEO & Managing Director. Jenni joined Cann as a Non-executive Director on 15 September 2020. In February 2024, Jenni stepped into an Executive Director role to provide financial oversight of the Company, transitioning to Interim CEO following the notice of resignation of the CEO on 21 March 2024. Chairman, Julian Chick, commented: "Since stepping in as Executive Director in February, Jenni has implemented a restructure and cost savings plan which will generate at least $2.15 million savings per annum. Following on from this, Jenni successfully managed the re-release of the Company's half-year financial report in May accompanied by an audit review report free from disclaimers, secured a further $5 million debt to fund the business, and achieved the ASX's reinstatement of CAN securities to trading in June. Jenni has over 15 years of senior finance executive experience in the medical, biotechnology and technology sectors, within small-mid cap ASX-listed companies. In addition to financial management, investor relations and corporate governance experience, Jenni has successfully completed multiple capital raisings and M&A transactions, including company acquisitions, asset sales, and a takeover defense. Most recently, Jenni was Chief Financial Officer & Company Secretary of technology communications company Whispir Ltd, and prior to that was CFO & Company Secretary of digital imaging company, Mach7 Technologies. She has also previously held CFO roles with Australia biotechnology companies Alchemia Limited and Mesoblast Limited. Jenni is a member of Chartered Accountants Australia & New Zealand, a Graduate of the Governance Institute of Australia, and has a Bachelor of Business Studies (majoring in accounting) from Massey University in New Zealand. Ms. Pilcher will be appointed for a fixed term ending on 1 July 2025, subject to termination by either party. The fixed term can be extended at any time by mutual agreement, in writing, between Ms. Pilcher and the Company.
Board Change • Jun 05Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Doug Rathbone was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Mar 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$20m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$20m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 24% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (€16.3m market cap, or US$17.7m).
お知らせ • Jan 08+ 1 more updateCann Group Limited Appoints Tony Di Pietro as Joint Company Secretary of Head of Legal and Regulatory AffairsCann Group Limited announced that Tony Di Pietro will act as joint Company Secretary with Steven Notaro, Head of Legal and Regulatory Affairs at Cann Group. . Having spent the past two decades at ASX-listed companies, Mr. Di Pietro boasts extensive experience as CFO/Company Secretary in the med-tech industry, with his last three roles at Sienna Cancer Diagnostics Limited (November 2014 - July 2020), INOVIQ Limited (July 2020 - November 2022) and Genetic Technologies Limited (November 2022 - present). In his most recent role at Genetic Technologies, Mr. Di Pietro managed a capital raising of $5 million from US-based investors and was responsible for both US and Australian due diligence activities and compliance with both ASX/Corporations Act & NASDAQ/SEC regulations. Mr. Di Pietro's qualifications include: A Bachelor of Commerce (BCom),Accounting and Finance, from Swinburne University of Technology;Chartered Accountants (CA) accreditation (1989-2000); Graduate Diploma of Applied Corporate Governancefrom the Governance Institute of Australia(2012-2014); and Completed the Company Directors Course at the Australian Institute of Company Directors in 2018.
お知らせ • Dec 04+ 1 more updateCann Group Limited Announces Resignation of Deborah Ambrosini as Chief Financial Officer, Effective December 22, 2023Cann Group Limited announced that its Chief Financial Officer Deborah Ambrosini, has resigned for personal reasons effective December 22, 2023.
お知らせ • Nov 22+ 1 more updateCann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.3756 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.3756 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,333,333 Price\Range: AUD 0.11268 Transaction Features: Subsequent Direct Listing
お知らせ • Aug 29Cann Group Limited, Annual General Meeting, Oct 26, 2023Cann Group Limited, Annual General Meeting, Oct 26, 2023, at 10:00 AUS Eastern Standard Time.
Reported Earnings • Aug 28Full year 2023 earnings released: AU$0.091 loss per share (vs AU$0.079 loss in FY 2022)Full year 2023 results: AU$0.091 loss per share (further deteriorated from AU$0.079 loss in FY 2022). Revenue: AU$21.7m (up 93% from FY 2022). Net loss: AU$33.8m (loss widened 28% from FY 2022). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
New Risk • Aug 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$35m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 35% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (€31.6m market cap, or US$34.2m).
お知らせ • Jul 26Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 11.658446 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 11.658446 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 97,153,716 Price\Range: AUD 0.12 Discount Per Security: AUD 0.0024 Security Features: Attached Options Transaction Features: Rights Offering
お知らせ • Jul 06Cann Group Limited Provides Revenue Guidance for the Year Ended June 30, 2023Cann Group Limited provided revenue guidance for the year ended June 30, 2023. Cann expects to report unaudited product sales revenue of approximately $13.5 million, before accounting for services, for the 12 months ending 30 June 2023 representing a 111% increase on FY22 revenue ($6.4 million). Strong market demand saw revenue from the sale of dried flower products increase by approximately 500% on FY22 and is the base for continued growth as the company scales up production. This improvement was driven by the domestic market, with the strong sales momentum supported by new clients entering into supply agreements, and several existing clients with repeat orders. Customer acquisition has been strengthened by Cann's ability to supply consistent quality, GMP product from the flagship facility in Mildura, achieved through state- of-the-art cultivation and manufacturing processes. FY23 production output at Mildura was 2.2 tonnes. In May 2023, Cann planted the largest crop in the Company's history, representing 8 tons annualised yield. This crop will be harvested in July 2023.
Reported Earnings • Feb 26First half 2023 earnings released: AU$0.053 loss per share (vs AU$0.028 loss in 1H 2022)First half 2023 results: AU$0.053 loss per share (further deteriorated from AU$0.028 loss in 1H 2022). Net loss: AU$18.8m (loss widened 128% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.
お知らせ • Jan 20Cann Group Limited Announces Preliminary Results from Their Phase 3 Clinical TrailCann Group Limited announced preliminary results from their Phase 3 clinical trail. Trial compared the efficacy of low dose Satipharm® CBD capsules to placebo in treating sleep disturbances. Three doses of Satipharm® CBD capsules were compared to placebo in a randomised, double-blind, placebo-controlled, multicentre clinical trial that included a total of 257 participants with sleep disturbances. Preliminary view of the analysis of the primary end-points have not shown a statistically superior response compared to placebo. Cann Group expects these trial results will delay submission of the registration application to the Therapeutic Goods Administration (TGA) for this indication. Once the full data set (including the secondary end-points) and report of the clinical trial is delivered to the company, Cann Group will evaluate the data and review its approach for this indication. A market update will be published once that review is complete.
お知らせ • Jan 10Cann Group Limited Announces Chief Executive Officer ChangesCann Group Limited announced that Peter Koetsier has been appointed to the role of Chief Executive Officer (CEO) and will commence in the role on January 16, 2023. Mr. Koetsier will replace Peter Crock, who was appointed on April 19, 2016 and announced on October 24, 2022 that he would be stepping down as CEO of the Company. Mr. Koetsier brings to Cann more than 30 years of general management, marketing and commercial leadership roles within global pharmaceutical companies. He has most recently been Head of Asia Pacific for French biopharmaceutical company, Ipsen, where he developed and led the implementation of a successful growth strategy which included the commercial launch of new brands. Previous roles include General Manager of Australia/New Zealand (Ipsen) and senior management positions with Astra/Zeneca, UK, and Bristol-Myers Squibb in Europe. Mr. Koetsier has a bachelor's degree in science (pharmacology, immunology) and a diploma in education (science, biology) from Monash University and is a graduate of the INSEAD CEDEP General Management Program.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Doug Rathbone was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 30Full year 2022 earnings released: AU$0.079 loss per share (vs AU$0.098 loss in FY 2021)Full year 2022 results: AU$0.079 loss per share. Revenue: AU$11.2m (up 32% from FY 2021). Net loss: AU$26.5m (loss widened 5.4% from FY 2021).
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Doug Rathbone was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 21First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: AU$0.028 loss per share (up from AU$0.05 loss in 1H 2021). Net loss: AU$8.28m (loss narrowed 12% from 1H 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 277%, compared to a 7.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings.
Executive Departure • Sep 07Chief Financial Officer Greg Bullock has left the companyDuring their tenure, earnings grew by 46% annually compared to the industry average of 8.2%. On the 1st of September, Greg Bullock left the company after 1.3 in the role. We don't have any record of a personal shareholding under Greg's name. Greg is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.42 years, which is considered inexperienced in the Simply Wall St Risk Model.
Reported Earnings • Aug 24Full year 2021 earnings released: AU$0.097 loss per share (vs AU$0.12 loss in FY 2020)Full year 2021 results: Net loss: AU$25.1m (loss widened 48% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Feb 24First half 2021 earnings released: AU$0.05 loss per share (vs AU$0.06 loss in 1H 2020)First half 2021 results: Net loss: AU$9.40m (loss widened 12% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 41% per year whereas the company’s share price has fallen by 39% per year.
Is New 90 Day High Low • Feb 10New 90-day high: €0.52The company is up 167% from its price of €0.19 on 11 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period.
Is New 90 Day High Low • Nov 24New 90-day high: €0.30The company is up 21% from its price of €0.25 on 26 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Oct 12New 90-day low: €0.23The company is down 54% from its price of €0.50 on 14 July 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 7.0% over the same period.